Delphi Diagnostics

Delphi Diagnostics guides personalized breast cancer therapy decisions with the Endocrine Activity Index

Home » Technology » Intellectual Property

Intellectual Property

  • Delphi Diagnostics holds exclusive worldwide rights to commercialize breast cancer diagnostics developed by Dr. Fraser Symmans at University of Texas MD Anderson Cancer Center in Houston, Texas. 
  • Delphi Diagnostics owns rights to two separate patent families currently encompassing its diagnostic technologies including SET (Sensitivity to Endocrine Therapy) and RCB (Residual Cancer Burden). 
  • Patents are granted or pending in US, Brazil, Canada, Japan, Israel and the EU (including Great Britain). 

Patents

The following Delphi Diagnostics, Inc. products may be covered by one or more patents as indicated below:

Notice is hereby provided under 35 U.S.C. §287(a) for the following products:

SETER/PRTM The listed products and their use are the subject of US Patent Nos.:
US 11,459,617
SET2,3 TM The listed products and their use are the subject of US Patent Nos.:
US 11,459,617